Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2014-03-25 Capital/Financing Update
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Bijzonder verslag van de Raad aan de aandeelhouders.pdf
Capital/Financing Update Classification · 95% confidence The document is titled "BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR AAN DE AANDEELHOUDERS over het gebruik van het toegestane kapitaal en de nagestreefde doeleinden opgesteld overeenkomstig artikel 604 van het Wetboek van vennootschappen" (Special Report of the Board of Directors to the Shareholders concerning the use of authorized capital and the intended purposes, drawn up in accordance with Article 604 of the Companies Code). This document details the proposal to grant the Board of Directors the authority to increase capital (issuing shares, convertible bonds, or warrants) under specific conditions and for defined purposes, which is a matter requiring shareholder approval, typically presented ahead of a General Meeting. This content strongly aligns with materials presented to shareholders regarding corporate governance, capital structure changes, and voting matters. Since it is a detailed report/proposal intended for shareholder decision-making regarding capital authorization, it is most closely related to the scope of a proxy solicitation or information statement, or potentially a specific type of capital/financing update presented to shareholders. Given the context of proposing authorization for capital changes to shareholders, it fits best under 'Capital/Financing Update' (CAP) as it directly concerns the structure and authorization for future capital actions, or potentially 'Proxy Solicitation & Information Statement' (PSI) if it were explicitly part of a meeting agenda package. However, the core subject is the authorization of capital increase mechanisms. Since it is a detailed report explaining the mechanism and purpose of authorized capital, and not just a simple announcement of a dividend or a general management report, 'CAP' (Capital/Financing Update) is a strong candidate, but the structure suggests it is a formal report presented to shareholders for approval, which often accompanies proxy materials. Looking at the definitions, 'CAP' covers updates on fundraising/financing activities. This document is a proposal *to enable* future financing activities. Given the detailed legal explanation regarding capital increase mechanisms (Article 604 W.Venn.), it is a specific corporate governance/capital structure document. In many jurisdictions, such a proposal is presented in the context of an AGM or EGM, often detailed in a Proxy Statement (PSI). Since it is a detailed report explaining the mechanism for future capital changes, 'CAP' is the most direct fit for the subject matter (capital structure change authorization). If it were a simple announcement of a dividend or share repurchase, other codes would apply. Since it is a formal report detailing the proposed authorization for capital changes, I classify it as CAP.
2014-03-25 Dutch
140311 - Bio - Davies Kay vFinal.pdf
Board/Management Information Classification · 95% confidence The document text provided is a biographical sketch of Professor Dame Kay Davies CBE, detailing her academic positions, research interests, publications, and board involvements (e.g., Wellcome Trust, UCB's Science Advisory Board). This content strongly suggests information related to the composition of the company's leadership or oversight body, such as the Board of Directors or senior management team. This aligns best with the 'Board/Management Information' category.
2014-03-25 English
Agenda FR.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES' (Shareholders' General Meeting) and lists an 'AGENDA' covering ordinary and special business. The agenda items include voting on annual accounts, remuneration reports, director appointments (A.8), approval of a free share program (A.9), and crucially, seeking shareholder approval for 'change of control' clauses in various financing agreements (EMTN Program, retail bonds, credit agreements) as required by Article 556 of the Belgian Companies Code (A.10). This content structure—a formal agenda for a meeting where key corporate governance and financial resolutions are put to a vote—is the defining characteristic of materials related to an Annual General Meeting (AGM). Although it discusses remuneration (DEF 14A topic) and capital changes (SHA topic), the overarching context is the meeting itself. Therefore, the most appropriate classification is AGM Information.
2014-03-25 French
Verslag van de Raad van Bestuur.pdf
Management Reports Classification · 95% confidence The document is a 'Jaarverslag van de Raad van Bestuur' (Annual Report of the Board of Directors) for UCB NV, presented to the General Meeting. It contains specific financial data, including balance sheet figures, profit distribution proposals, dividend declarations, and details on capital structure changes (share issues, bond issuances, and liquidations). While it references the broader 'Jaarverslag 2013' (Annual Report) of the UCB Group, this specific document serves as the statutory management report for the parent company, providing substantive financial analysis and results for the fiscal year 2013. It is not merely an announcement (RPA) or a certification, but a comprehensive management report detailing financial performance and outlook. FY 2013
2014-03-25 Dutch
140310 - Bio - Cédric van Rijckevorsel.pdf
Board/Management Information Classification · 99% confidence The document text provides a detailed biography and professional history of an individual, Cédric van Rijckevorsel, mentioning his roles as a Chartered Financial Analyst, his career progression through various financial institutions (ING Group, Fortis Group, Lombard Odier & Cie, Bank Syz), and his current directorships (IDS Capital SA, Financière de Tubize SA). This type of biographical information, especially concerning board members or key personnel, strongly aligns with documents related to corporate governance or management structure. Given the options, 'Board/Management Information' (MANG) is the most appropriate classification for a profile of a director/executive.
2014-03-25 English
Comptes annuels UCB SA 2013.pdf
Annual Report Classification · 95% confidence The document is a formal Belgian statutory filing ('COMPTES ANNUELS' or Annual Accounts) for UCB SA. It includes specific fiscal period data (2013), board member listings, and official registration details required by the Belgian National Bank. While it is part of the annual reporting process, it represents the official statutory financial filing rather than a narrative 10-K or a general investor report. Given the structure and content, it is classified as an Annual Report (10-K equivalent for this jurisdiction). FY 2013
2014-03-25 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.